Department of Neurology, University of Utah Health, Salt Lake City, Utah, USA
Neurology, NYU School of Medicine, Brooklyn, New York, USA.
J Neurointerv Surg. 2020 Nov;12(11):1045-1048. doi: 10.1136/neurintsurg-2020-016777. Epub 2020 Sep 28.
We aimed to compare the outcome of acute ischemic stroke (AIS) patients who received endovascular thrombectomy (EVT) with confirmed COVID-19 to those without.
We performed a retrospective analysis using the Vizient Clinical Data Base and included hospital discharges from April 1 to July 31 2020 with ICD-10 codes for AIS and EVT. The primary outcome was in-hospital death and the secondary outcome was favorable discharge, defined as discharge home or to acute rehabilitation. We compared patients with laboratory-confirmed COVID-19 to those without. As a sensitivity analysis, we compared COVID-19 AIS patients who did not undergo EVT to those who did, to balance potential adverse events inherent to COVID-19 infection.
We identified 3165 AIS patients who received EVT during April to July 2020, in which COVID-19 was confirmed in 104 (3.3%). Comorbid COVID-19 infection was associated with younger age, male sex, diabetes, black race, Hispanic ethnicity, intubation, acute coronary syndrome, acute renal failure, and longer hospital and intensive care unit length of stay. The rate of in-hospital death was 12.4% without COVID-19 vs 29.8% with COVID-19 (P<0.001). In mixed-effects logistic regression that accounted for patient clustering by hospital, comorbid COVID-19 increased the odds of in-hospital death over four-fold (OR 4.48, 95% CI 3.02 to 6.165). Comorbid COVID-19 was also associated with lower odds of a favorable discharge (OR 0.43, 95% CI 0.30 to 0.61). In the sensitivity analysis, comparing AIS patients with COVID-19 who did not undergo EVT (n=2139) to the AIS EVT patients with COVID-19, there was no difference in the rate of in-hospital death (30.6% vs 29.8%, P=0.868), and AIS EVT patients had a higher rate of favorable discharge (32.4% vs 47.1%, P=0.002).
In AIS patients treated with EVT, comorbid COVID-19 infection was associated with in-hospital death and a lower odds of favorable discharge compared with patients without COVID-19, but not compared with AIS patients with COVID-19 who did not undergo EVT. AIS EVT patients with COVID-19 were younger, more likely to be male, have systemic complications, and almost twice as likely to be black and over three times as likely to be Hispanic.
我们旨在比较接受血管内血栓切除术 (EVT) 的确诊 COVID-19 的急性缺血性脑卒中 (AIS) 患者与未确诊 COVID-19 的患者的结局。
我们使用 Vizient 临床数据库进行了回顾性分析,纳入了 2020 年 4 月 1 日至 7 月 31 日的 ICD-10 编码为 AIS 和 EVT 的出院记录。主要结局为住院期间死亡,次要结局为出院时情况良好,定义为出院回家或到急性康复病房。我们比较了实验室确诊 COVID-19 的患者与未确诊 COVID-19 的患者。作为敏感性分析,我们比较了未接受 EVT 的 COVID-19 AIS 患者与接受 EVT 的患者,以平衡 COVID-19 感染固有的潜在不良事件。
我们确定了 3165 名在 2020 年 4 月至 7 月期间接受 EVT 的 AIS 患者,其中 104 名(3.3%)确诊 COVID-19。合并 COVID-19 感染与年龄较小、男性、糖尿病、黑人、西班牙裔、插管、急性冠状动脉综合征、急性肾衰竭以及更长的住院和重症监护病房住院时间有关。无 COVID-19 的住院期间死亡率为 12.4%,而有 COVID-19 的住院期间死亡率为 29.8%(P<0.001)。在考虑了按医院分组的患者聚类的混合效应逻辑回归中,合并 COVID-19 使住院期间死亡的几率增加了四倍以上(OR 4.48,95%CI 3.02 至 6.165)。合并 COVID-19 还与出院时情况良好的几率降低有关(OR 0.43,95%CI 0.30 至 0.61)。在敏感性分析中,将未接受 EVT 的 COVID-19 AIS 患者(n=2139)与接受 EVT 的 COVID-19 AIS 患者进行比较,住院期间死亡率没有差异(30.6%比 29.8%,P=0.868),而接受 EVT 的 AIS 患者的出院时情况良好的几率更高(32.4%比 47.1%,P=0.002)。
在接受 EVT 治疗的 AIS 患者中,与未感染 COVID-19 的患者相比,合并 COVID-19 感染与住院期间死亡和出院时情况良好的几率降低有关,但与未接受 EVT 的 COVID-19 AIS 患者相比并无差异。COVID-19 阳性的 AIS EVT 患者更年轻,更可能是男性,有全身并发症,黑人的几率几乎是两倍,西班牙裔的几率是三倍多。